Cargando…
Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before ra...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376769/ https://www.ncbi.nlm.nih.gov/pubmed/36158914 http://dx.doi.org/10.4254/wjh.v14.i7.1480 |
_version_ | 1784768205543178240 |
---|---|
author | Nakai, Masato Morikawa, Kenichi Hosoda, Shunichi Yoshida, Sonoe Kubo, Akinori Tokuchi, Yoshimasa Kitagataya, Takashi Yamada, Ren Ohara, Masatsugu Sho, Takuya Suda, Goki Ogawa, Koji Sakamoto, Naoya |
author_facet | Nakai, Masato Morikawa, Kenichi Hosoda, Shunichi Yoshida, Sonoe Kubo, Akinori Tokuchi, Yoshimasa Kitagataya, Takashi Yamada, Ren Ohara, Masatsugu Sho, Takuya Suda, Goki Ogawa, Koji Sakamoto, Naoya |
author_sort | Nakai, Masato |
collection | PubMed |
description | BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC. METHODS: In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative. RESULTS: In HCV-positive patients, only des-γ-carboxy-prothrombin ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, while M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; P < 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients. CONCLUSION: In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC. |
format | Online Article Text |
id | pubmed-9376769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-93767692022-09-23 Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma Nakai, Masato Morikawa, Kenichi Hosoda, Shunichi Yoshida, Sonoe Kubo, Akinori Tokuchi, Yoshimasa Kitagataya, Takashi Yamada, Ren Ohara, Masatsugu Sho, Takuya Suda, Goki Ogawa, Koji Sakamoto, Naoya World J Hepatol Observational Study BACKGROUND: The Mac-2 binding protein glycosylation isomer (M2BPGi), a fibrosis marker in various liver diseases, is reportedly a prognostic marker in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. AIM: To evaluate whether the M2BPGi value, M2BP, and pre-sarcopenia before radiofrequency ablation (RFA) could be useful recurrence and prognostic markers in patients with early-stage HCC. METHODS: In total, 160 patients with early-stage primary HCC treated with RFA were separately analyzed as hepatitis C virus (HCV)-positive and HCV-negative. Factors contributing to recurrence and liver-related death, including M2BP, M2BPGi, and skeletal muscle mass index, were statistically analyzed. Eighty-three patients were HCV-positive and 77 were HCV-negative. RESULTS: In HCV-positive patients, only des-γ-carboxy-prothrombin ≥ 23 mAU/mL was a significant poor prognostic factor affecting survival after RFA. In HCV-negative patients, M2BPGi ≥ 1.86 cutoff index was significantly associated with tumor recurrence, while M2BP was not. M2BPGi ≥ 1.86 cutoff index (hazard ratio, 4.89; 95% confidence interval: 1.97-12.18; P < 0.001) and pre-sarcopenia (hazard ratio, 3.34, 95% confidence interval: 1.19-9.37; P = 0.022) were independent significant poor prognostic factors in HCV-negative patients. CONCLUSION: In HCV-negative patients with primary HCC treated with RFA, lower M2BPGi contributed to a lower tumor recurrence rate and longer survival period. Pre-sarcopenia contributed to the poor prognosis independently in HCV-negative patients. These factors might be useful recurrence and prognostic markers for early-stage primary HCC. Baishideng Publishing Group Inc 2022-07-27 2022-07-27 /pmc/articles/PMC9376769/ /pubmed/36158914 http://dx.doi.org/10.4254/wjh.v14.i7.1480 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Observational Study Nakai, Masato Morikawa, Kenichi Hosoda, Shunichi Yoshida, Sonoe Kubo, Akinori Tokuchi, Yoshimasa Kitagataya, Takashi Yamada, Ren Ohara, Masatsugu Sho, Takuya Suda, Goki Ogawa, Koji Sakamoto, Naoya Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma |
title | Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma |
title_full | Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma |
title_fullStr | Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma |
title_full_unstemmed | Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma |
title_short | Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma |
title_sort | pre-sarcopenia and mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376769/ https://www.ncbi.nlm.nih.gov/pubmed/36158914 http://dx.doi.org/10.4254/wjh.v14.i7.1480 |
work_keys_str_mv | AT nakaimasato presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT morikawakenichi presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT hosodashunichi presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT yoshidasonoe presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT kuboakinori presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT tokuchiyoshimasa presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT kitagatayatakashi presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT yamadaren presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT oharamasatsugu presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT shotakuya presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT sudagoki presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT ogawakoji presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma AT sakamotonaoya presarcopeniaandmac2bindingproteinglycosylationisomeraspredictorsofrecurrenceandprognosisofearlystagehepatocellularcarcinoma |